Vaxcyte's Stock Surge: A Sign of Promise or a Valuation Trap?
Vaxcyte's shares have surged over 38% in three months, reigniting debate on whether the clinical-stage biotech is undervalued or if investors are overlooking significant risks in its unproven pipeline.